Last 48 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Bristol-Myers Squibb Company's quarterly P/E stands at 11.6x, down 8.9% year-over-year. EV/EBITDA has expanded 18.0% YoY to 10.7x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 15.65 | 11.57 | 25.44 | 10.44 | 18.08 | 12.71 | 400.57 | 21.56 | 12.51 | — | 14.74 | 15.60 | 16.15 |
| — | -8.9% | -93.6% | -51.6% | +44.6% | — | +2616.8% | +38.2% | -22.5% | — | -22.1% | -34.2% | -44.6% | |
| P/S Ratio | 2.29 | 2.70 | 2.20 | 1.88 | 1.92 | 2.77 | 2.33 | 2.21 | 1.73 | 2.31 | 2.27 | 2.73 | 2.99 |
| — | -2.7% | -5.7% | -14.9% | +11.3% | +20.0% | +2.7% | -19.1% | -42.3% | -28.4% | -32.2% | -19.7% | -14.0% | |
| P/B Ratio | 5.96 | 6.17 | 5.95 | 4.94 | 5.39 | 7.12 | 7.03 | 6.11 | 4.94 | 6.63 | 3.54 | 4.12 | 4.20 |
| — | -13.4% | -15.4% | -19.1% | +9.3% | +7.4% | +98.7% | +48.2% | +17.6% | +44.3% | -28.0% | -11.6% | -17.2% | |
| P/FCF | 8.58 | 40.93 | 17.16 | 3.84 | 6.63 | 18.33 | 7.09 | 4.99 | 10.21 | 10.76 | 6.65 | 6.79 | 20.64 |
| — | +123.2% | +141.9% | -23.1% | -35.0% | +70.5% | +6.7% | -26.6% | -50.6% | -20.9% | -48.5% | -38.8% | -0.8% | |
| EV / EBITDA | 8.89 | 10.71 | 16.37 | 6.87 | 6.45 | 9.08 | 8.85 | 7.61 | 6.37 | 9.70 | 7.60 | 8.35 | 9.44 |
| — | +18.0% | +85.1% | -9.8% | +1.2% | -6.4% | +16.3% | -8.8% | -32.5% | +7.1% | -30.2% | -13.1% | +0.7% | |
| EV / EBIT | 11.59 | 12.14 | 26.87 | 8.85 | 14.69 | 11.88 | 58.15 | 17.03 | 18.26 | — | 16.87 | 15.79 | 19.30 |
| — | +2.2% | -53.8% | -48.0% | -19.6% | — | +244.6% | +7.9% | -5.4% | — | -21.2% | -14.4% | -11.3% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Bristol-Myers Squibb Company's operating margin was 28.5% in Q1 2026, up 17.1 pp QoQ and down 3.0 pp YoY. The trailing four-quarter average of 25.8% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 7.2% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 67.6% | 70.2% | 67.2% | 71.9% | 65.8% | 65.5% | 60.2% | 55.6% | 55.7% | 55.5% | 56.6% | 56.7% | 54.6% |
| — | +7.2% | +11.8% | +29.2% | +18.0% | +18.0% | +6.3% | -1.9% | +2.1% | -3.4% | -0.6% | -1.3% | -4.5% | |
| Operating Margin | 26.3% | 28.5% | 11.4% | 29.8% | 33.6% | 31.4% | 20.5% | 19.2% | 21.2% | 12.9% | 17.0% | 19.2% | 17.3% |
| — | -9.4% | -44.7% | +54.8% | +58.4% | +143.0% | +20.6% | +0.3% | +22.4% | -40.2% | +13.2% | -3.5% | -23.5% | |
| Net Margin | 14.6% | 23.3% | 8.7% | 18.0% | 10.7% | 21.9% | 0.6% | 10.2% | 13.8% | -100.4% | 15.4% | 17.6% | 18.5% |
| — | +6.3% | +1389.0% | +76.8% | -22.5% | +121.8% | -96.2% | -42.1% | -25.4% | -603.1% | -13.4% | +22.8% | +54.5% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 40.4% | 13.9% | 5.9% | 12.2% | 7.5% | 14.5% | 0.4% | 7.1% | 10.0% | -51.7% | 6.0% | 6.3% | 6.5% |
| — | -4.4% | +1265.4% | +72.6% | -25.0% | +128.1% | -92.9% | +12.0% | +54.1% | -820.7% | -5.0% | +28.5% | +46.8% | |
| ROA | 7.7% | 3.0% | 1.2% | 2.3% | 1.4% | 2.7% | 0.1% | 1.3% | 1.7% | -12.3% | 1.9% | 2.1% | 2.2% |
| — | +14.3% | +1403.2% | +78.7% | -19.3% | +121.6% | -95.9% | -38.4% | -21.4% | -618.2% | -8.8% | +29.0% | +58.0% | |
| ROIC | 16.9% | 4.4% | 1.9% | 5.0% | 5.4% | 4.6% | 3.2% | 2.7% | 3.0% | 1.9% | 2.4% | 2.6% | 2.3% |
| — | -3.2% | -39.5% | +81.9% | +81.4% | +147.4% | +32.2% | +7.2% | +28.6% | -37.0% | +21.0% | -0.8% | -24.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Bristol-Myers Squibb Company's Debt/EBITDA ratio is 12.0x, down from 21.0x last quarter — elevated, raising questions about debt serviceability. The current ratio has improved 11.0% YoY to 1.42x, strengthening the short-term liquidity position. Debt/Equity has declined for 6 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.55 | 2.21 | 2.55 | 2.74 | 2.91 | 2.94 | 3.12 | 2.99 | 3.16 | 3.47 | 1.41 | 1.35 | 1.22 |
| — | -24.7% | -18.5% | -8.2% | -8.0% | -15.4% | +122.2% | +121.2% | +158.6% | +181.0% | +7.5% | +10.3% | -7.2% | |
| Debt / EBITDA | 2.85 | 11.99 | 21.00 | 11.02 | 9.90 | 11.30 | 11.61 | 10.53 | 10.43 | 14.12 | 9.39 | 8.65 | 8.96 |
| — | +6.1% | +80.9% | +4.6% | -5.1% | -19.9% | +23.6% | +21.8% | +16.4% | +75.0% | -2.3% | +3.9% | +9.7% | |
| Current Ratio | 1.26 | 1.42 | 1.26 | 1.27 | 1.21 | 1.28 | 1.25 | 1.24 | 1.16 | 1.11 | 1.43 | 1.18 | 1.39 |
| — | +11.0% | +0.2% | +2.1% | +4.4% | +15.2% | -12.2% | +5.3% | -17.0% | -21.8% | +14.5% | -16.8% | -3.5% | |
| Quick Ratio | 1.14 | 1.28 | 1.14 | 1.17 | 1.11 | 1.17 | 1.15 | 1.09 | 1.02 | 0.99 | 1.31 | 1.07 | 1.28 |
| — | +9.3% | -0.4% | +6.9% | +8.2% | +17.4% | -12.4% | +1.8% | -19.8% | -22.5% | +14.8% | -17.8% | -4.8% | |
| Interest Coverage | 7.08 | — | 26.82 | 7.49 | 4.66 | 7.01 | 1.35 | 4.32 | 3.47 | -26.10 | 6.30 | 8.57 | 7.59 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Deep dive into BMY consensus models and risk factors.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BMY stock.
Bristol-Myers Squibb Company's current P/E is 15.7x. The average P/E over the last 4 quarters is 16.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Bristol-Myers Squibb Company's current operating margin is 26.3%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Bristol-Myers Squibb Company's business trajectory between earnings reports.